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Abstract
Introduction Vertebroplasty (VP) is a cost-efficient
alternative to kyphoplasty; however, regarding safety and
vertebral body (VB) height restoration, it is considered
inferior. We assessed the safety and efficacy of VP in
alleviating pain, improving quality of life (QoL) and
restoring alignment.
Methods In a prospective monocenter case series from
May 2007 until July 2008, there were 1,408 vertebropla-
sties performed during 319 interventions in 306 patients
with traumatic, lytic and osteoporotic fractures. The
249 interventions in 233 patients performed because of
osteoporotic vertebral fractures were analyzed regarding
demographics, treatment and radiographic details, pain
alleviation (VAS), QoL improvement (NASS and EQ-5D),
complications and predictors for new fractures requiring a
reoperation.
Results The osteoporotic patient sample consisted of
76.7% (179) females with a median age of 80 years. A total
of 54 males had a median age of 77 years. On average,
there were 1.8 VBs fractured and 5 VBs treated. The pre-
operative pain was assessed by the visual analog scale
(VAS) and decreased from 54.9 to 40.4 pts after 2 months
and 31.2 pts after 6 months. Accordingly, the QoL on the
EQ-5D measure (-0.6 to 1) improved from 0.35 pts before
surgery to 0.56 pts after 2 and to 0.68 pts after 6 months.
The preoperative Beck Index (anterior height/posterior
height) improved from a mean of 0.64 preoperative to 0.76
postoperative, remained stable at 2 months and slightly
deteriorated to 0.72 at 6 months postoperatively. There
were cement leakages in 26% of the fractured VBs and in
1.4% of the prophylactically cemented VBs; there were
symptoms in 4.3%, and most of them were temporary
hypotension and one pulmonary cement embolism that
remained asymptomatic. The univariate regression model
revealed a tendency for a reduced risk for new or refractures
on radiographs (OR = 2.61, 95% CI 0.92–7.38, p = 0.12)
and reoperations (OR = 2.9, 95% CI 0.94–8.949, p = 0.1)
when prophylactic augmentation was performed. The final
multivariate regression model revealed male patients to
have an about three times higher refracture risk (radio-
graphic) (OR = 2.78, p = 0.02) at 6 months after surgery.
Patients with a lumbar index fracture had an about three to
five times higher refracture/reoperation risk than patients
with a thoracic (OR = 0.33/0.35, p = 0.009/0.01) or
thoracolumbar (OR = 0.32/0.22, p = 0.099/0.01) index
fracture.
Conclusion If routinely used, VP is a safe and effica-
cious treatment option for osteoporotic vertebral fractures
with regard to pain relief and improvement of the QoL.
Even segmental realignment can be partially achieved
with proper patient positioning. Certain patient or fracture
characteristics increase the risk for early radiographic
refractures or new fractures, or a reoperation; a conse-
quent prophylactic augmentation showed protective ten-
dencies, but the study was underpowered for a final
conclusion.
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Introduction
A painful vertebral fracture can be a significant burden for
patients, limiting physical function and quality of life
(QoL), and increasing social isolation [1, 2]. The fractures
may cause depression and can result in decreased mobility,
loss of independence and increased mortality because of a
reduction in lung capacity and abdominal space with a
consequent loss of appetite [3, 4]. Percutaneous verteb-
roplasty (VP) has been used for the treatment of osteopo-
rotic compression fractures, aggressive hemangiomas and
osteolytic neoplasms. Polymethylmethacrylate bone
cement (PMMA) is injected into a fractured vertebral body
(VB) through one or two bone biopsy needles [3]. The
cement is directly injected into the fractured vertebra
without creation of a void unlike in balloon kyphoplasty
(BKP). Re-establishment of lost VB height is not possible
with the procedure per se, but can possibly be achieved
with additional positioning maneuvers [5]. Height resto-
ration, however, is not the main goal of VP, but rather
prevention of further segmental or spinal malalignment,
pain reduction, increased mobility and improved QoL.
The current article reports on the early results of 233
patients with one or several osteoporotic fractures in an
academic center with a high annual volume of VPs.
Materials and methods
Information was prospectively collected on standardized
scannable case report forms in the framework of the
research program for the treatment of osteoporotic frac-
tures of the Association for the Study of Internal Fixation
(AO/AO-ASIF). The data were then entered into the
MEMdoc online database (http://www.memdoc.org) of the
Institute for Evaluative Research in Medicine (IEFM) at
the University of Bern [6].
The following documentation forms and outcome
instruments were used: (a) surgeon-administered primary
intervention form and follow-up form; (b) for patient
assessment, Euroqol-5D, NASS, and comorbidity ques-
tionnaire; (c) patient consent form; and (d) one annotation
form about the study and its purpose.
At the time of surgery, the primary intervention form
was completed by the surgeon. Informed consent about
participation had to be given by the patient as well as a
completed Euroqol-5D, NASS, and comorbidity question-
naires preoperatively and at every follow-up examination
after 8 weeks, 6 months, 1 year and 2 years.
The current article reports on the 6-month follow-up of
the study. A total of 636 EQ-5D and 638 NASS forms
for the evaluation of general and disease-specific QoL
and 175 comorbidity questionnaires were available for
analysis.
Patient sample
Overall sample
In this prospective case series, 306 patients were treated
with a percutaneous VP between May 2007 and July 2008.
They underwent a total of 319 VP interventions with 1,408
treated levels; 29 repeat interventions were done in
29 patients for new fractures after primary surgery.
Exclusion criteria for the study were VP in combination
with a rigid stabilization of the spine and a fracture older
than 6 months or without reparative activity on MRI.
There were 214 (69.9%) females and 92 (30.1%) males
with a mean age of 75 years (range 28.3–94.1 years) and
71 years (range 35–92.7 years). The overall distribution of
underlying diagnoses was osteoporosis in 73% (233 cases),
trauma in 14.7% (47 cases) and lytic lesions in 12.3%
(39 cases). Stratified by sex, there was osteoporosis in
83.6% (179 patients), trauma in 7.5% (16 patients) and
lytic lesions in 8.9% (19 patients) of females. In the male
patient group, there were 58.7% (54 patients) of cases with
osteoporosis, 26.1% (24 patients) with trauma and 15.2%
(14 patients) with lytic lesions.
Study sample with osteoporosis
The osteoporotic patient sample consisted of 76.7% (179)
females with a median age of 80 years. The 54 males had a
median age of 77 years. Figure 1 shows the comorbidities
of the osteoporotic patient sample. On average, there were
1.8 VBs fractured, but an average of five levels was aug-
mented. Regarding AO fracture types, there were 19.4%
A.1.1, 48.2% A.1.2, 15.8% A.3.1 and 16.5% other fracture
types. The most frequently performed cementations were in
6 (30.9%), 3 (21.5%) or 5 (19.74%) levels. About 36.5% of
the interventions were localized at the thoracolumbar
junction (Th12–L2). MRI was not routinely used for
assessing the fracture age, i.e., reparative activity. Only in
those cases where multiple old and new fractures were
present, the MRI and fracture edema were used for
selecting the levels to be augmented.
The preoperative American Society of Anesthesiologists
(ASA) status of the osteoporotic patients was ASA 1 or 2 in
25.3% (59 interventions), ASA 3 or 4 in 64.8% (151
interventions), 6.9% (16 interventions) unspecified and not
recorded in 3.0%. There were 23 repeat interventions in
this group.
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Osteoporosis was either defined based on dual axial
absorptiometry (DXA) conducted during a current treatment
in the hospital’s department of osteoporosis (internally
referred cases, about 50%) or based on anamnesis and risk/
comorbidity profile of the patient. The main diagnosis could
be specified as ‘‘osteoporosis,’’ ‘‘trauma’’, ‘‘lytic lesion’’ or a
combination. For the current analysis, only cases with the
main diagnosis of ‘‘osteoporosis’’ were considered; this
corresponds to a spontaneous or low-energy osteoporotic
fracture. Cases with ‘‘trauma’’ and ‘‘osteoporosis’’ marked,
e.g., slipping in a bathtub with a consequent fracture, were
excluded.
We also divided the osteoporotic group based on the
type of prophylactic augmentation into:
Type 1 (84 cases): cranio/caudal (one or two-sided)
augmentation of the directly adjacent vertebral
body(ies) and augmentation of the fractured VB.
There were 76% females with a mean age of
75 years; males were 73 years old.
Type 2 (43 cases): one sided multilevel prophylaxis.
There were 65% females with a mean age of
78 years; males were 74 years old.
Type 3 (105 cases): cranio/caudal (two-sided) multilevel
prophylaxis. There were 82% females with a
mean age of 78 years; males were 79 years old.
Statistical analysis
Wilcoxon’s rank-sum and signed-rank test were used for
comparisons between baseline and follow-up examinations
of continuous variables such as the pain visual analog scale
(VAS). When comparing proportions, the chi-square test
was used and McNemar’s test for matched pairs.
For binary outcomes, the search for predictors was con-
ducted with univariate and multivariate logistic regression
models with backward elimination of non-significant co-
variates and checked with stepwise model selection. Odds
ratios and 95% confidence intervals of significant predictors
were reported. The a was set to 0.05 throughout the study. All
statistical analyses were conducted using SAS 9.1 (SAS
Institute Inc., Cary, NC, USA). Power analyses were con-
ducted with PASS 2008 (NCSS, LLC, Kaysville, UT, USA).
Results
Pain relief
One of the main advantages of VP is the fast and effective
pain reduction. Pain was assessed by VAS scores using the
NASS questionnaire.
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Fig. 1 Comorbidity profile of
the patient group with
osteoporotic fractures
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The mean preoperative back pain was 54.9 points. At the
2 months follow-up it was reduced to 40.4 points and
further to 31.2 points at 6 months (both p \ 0.0001).
Reduction in pain medication
A significant reduction in painkiller consumption was
revealed. The amount of patients who did not need any
pain medication increased from 12.5% preoperative to
52.7% at the 2 months follow-up and 62.2% at 6 months
(p \ 0.0001). The number of patients consuming
acetaminophen decreased, from 33.9% before the inter-
vention to 11.6% at 2 months (p \ 0.0001) and 8.6% at
6 months postoperatively (p \ 0.0001). The consumption
of metamizole decreased from 10.7% preoperatively to
2.2% at the 2 months (p \ 0.0001) and to 1.72 at the
6 months follow-up (p \ 0.0001).
The consumption of nonsteroidal anti-inflammatory
drugs (NSAIDs) decreased from 9% before the intervention
to 3.4% at 2 months postoperatively (p = 0.0093) and to
1.7% at 6 months (p = 0.0007). Morphine and morphine
derivates were needed by 20.2% of patients before surgery.
This number was reduced to 4.3% after 2 months and
(p \ 0.0001) and to 3.4% after 6 months (p \ 0.0001).
Segmental kyphosis and alignment
For the evaluation of the segmental kyphosis and align-
ment, 162 patients whose 2-month radiographs were
available for analysis were radiologically assessed; for the
6 months measurements, 85 patients’ radiographs were
available.
The average preoperative anterior VB height (AO
fracture types 1.2 and 3.1) was 16.7 mm (range 33.6–
2.8 mm), improved immediately postoperative to 20.2 mm
(p \ 0.0001) (range 7.7–33.8 mm), and slightly decreased
after 2 months with an average of 19.5 mm (range 9.6–
33.3 mm) and after 6 months to 20 mm (range
10.0–31.8 mm).
The middle VB height was increased from a preopera-
tive average of 16.8 mm (range 5.3–31.4) to 20.0 mm
(p \ 0.0001) (range 9.1–31.4) postoperatively, and after
2 months to 19.7 mm (range 10.8–29.8) and after 6 months
to 20.2 mm (range 10.6–31.6 mm).
The average preoperative Beck Index (anterior height
divided by posterior height, AO fracture types 1.2 and 3.1)
was 0.64 (range 0.15–1.1); the immediate postoperative
one was 0.76 (p \ 0.0001) (range 0.29–1.4), which
decreased slightly to 0.75 (range 0.35–1.51) after 2 months
and further to 0.72 (range 0.4–1.0) after 6 months.
Alternative Beck Index (middle height divided by
posterior height).
The average alternative preoperative Beck Index was
0.65 (range 0.28–1.3); the immediate postoperative one
was 0.7 (p \ 0.0001) (range 0.37–1.22), 0.74 (range
0.37–1.02) after 2 months (p \ 0.0001) and 0.74 (range
0.54–0.98) after 6 months.
The preoperative local sagittal angle (angle of the superior
and inferior end plates, AO fracture types 1.2 and 3.1) was
improved from an average 14.1 (range 0.2–37.7) to 10.1
(range 0.2–30.6) postoperatively (p \ 0.0001), 10.7
(range 0.1–28.6) after 2 months (p \ 0.0001) and
11.9 (range 0.9–23.1) after 6 months (p \ 0.001).
Fractured VBs—Genant classification
According to the Genant classification, a semiquantitative
technique for assessment of fracture-related vertebral
deformity [7], no patient had a preoperative class 0 fracture
(no deformity); 12.7% (19 VBs) were class 1 (mild
deformity), 32% (48 VBs) class 2 (moderate deformity)
and 55.3% (83 VBs) class 3 (severe deformity). Postoper-
atively, 0.9% (2 VBs) were class 0, 20.1% (43 VBs) class
1, 58.9% (126 VBs) class 2 and 20.1% (43 VBs) class 3.
Two months postoperatively, there was 1 (0.6%) fracture
class 0; 20.5% (33 VBs) were class 1, 64% (103 VBs) class
2, and 15% (24 VBs) class 3. At 6 months, there was one
(1.19%) fracture class 0; 25% (21 VBs) were class 1,
58.3% (49 VBs) class 2 and 15.5% (13 VBs) class 3.
QoL improvement
Possible values of the EQ-5D range from 1 (best possible
QoL) to -0.6 (QoL worse than death). On preoperative
examination, the mean EQ-5D score was 0.35 points. It
improved to 0.56 points at the 2-month follow-up
(p = 0.0007) and further to 0.68 (p \ 0.001) points at the
6-month follow-up. Before the intervention, 23.1% (27
patients) of patients indicated a QoL below zero. At the
2-month follow-up, this percentage was reduced to 5.3% (5
patients) and to 1.19% (1 patient) at 6 months.
Cemented levels—fractured levels
In total, 1,121 VBs were cemented in the group with
osteoporosis as an underlying diagnosis. The most fre-
quently treated levels were L1 in 14.3% (160 VBs), L2 in
13.3% (149 VBs) and Th12 in 13.1% (147 VBs) of the
cases. Of the 1,121 cemented levels, 415 had a fracture
(37%). The most frequent fracture locations were L1
(16.9%, 61 cases), L2 (15.2%, 55 cases) and TH12 (14.4%,
52 cases). The other 706 levels (63%) were prophylacti-
cally cemented. Hence, with each fractured VB, about two
others were prophylactically augmented (Fig. 2).
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Subsequent new or refractures or reoperations
at the 2- and 6-month follow-up
For risk assessment of new fractures or refractures, defined
as change of one Genant class on radiographs, or reoper-
ation risks depending on the extent of preventive aug-
mentation, we analyzed the three prophylactic groups with
patients who had been radiologically assessed or followed
up by telephone. Two-month rates of new fractures or re-
fractures in these three groups were 18.2, 13.0 and 8.5%,
respectively. Six-month rates of new fractures or refrac-
tures in these three groups were 21.6, 14.3 and 9.6%,
respectively. Reoperation rates at 2 months after surgery
were 16, 11.7 and 6.4%, and at 6 months after surgery they
were 18.9, 11.7 and 7.5, respectively.
Cement extrusions
There were 1,121 cemented VBs with 415 fractured and
706 prophylactically cemented levels in the osteoporotic
patient sample. Overall, 118 (6.3%) cement extrusions
were documented, based on the assessment of intraopera-
tive AP and lateral fluoroscopic imaging of each treated
level. For the fractured VBs, the extrusion rate was 26%
(108/415) and for the prophylactically augmented VBs
1.4% (10/706). The direction of extrusions is displayed in
Fig. 3.
Some authors seem to not consider the intradiscal
extrusions as true extrusions or even provoke or undertake
these ‘‘discoplasties’’ intentionally. If deducting this type
of extrusion, the total rate of cement extrusions drops to
15.4% for the fractured VBs. None of these extrusions
caused local or systemic symptoms.
Intraoperative complications
Intraoperative complications were seen in 4.3% (10 cases).
They comprised nine temporary hypotensions after cement
injection (3.9%) and one nonsymptomatic cement embo-
lism (0.4%).
Postoperative experience of a patient
with the procedure
At the 2-month follow-up, 69.7% (62 cases) of patients
indicated that their condition had improved, 6.7% (6 cases)
considered the situation as ‘‘stable’’, 5.6% (5 cases) had
declined, and 18% (16 cases) found the time too early to
decide.
A total of 77.6% (76 cases) of the patients would
undergo the same operation getting the same result ‘‘cer-
tainly’’ or ‘‘probably’’; 19.4% (19 cases) were not sure and
only 3.1% (3 cases) would ‘‘probably’’ or ‘‘certainly’’ not
undergo the operation again.
Fig. 2 Frequency of cemented and fractured vertebral bodies
Fig. 3 Direction of cement extrusions
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At the 6-month follow-up, 76.5% (62 cases) of patients
indicated that their condition felt ‘‘much’’ or ‘‘slightly’’
better; 12.4% (10 cases) considered the situation as ‘‘sta-
ble’’, 8.6% (7 cases) had declined, and 2.5% (2 cases)
found the time too early to decide.
A total of 83.3% (70 cases) of the patients would
undergo the same operation getting the same result ‘‘cer-
tainly’’ or ‘‘probably’’; 10.7% (9 cases) were not sure and
only 3.6% (3 cases) would ‘‘probably’’ or ‘‘certainly’’ not
undergo the operation again.
Predictors for new factures or refractures or reoperation
at 6 months after surgery
In a univariate analysis, we searched for predictors of the
above events and included the following covariates in the
analysis: prophylaxis index new, defined as the number of
augmented levels divided by the number of new fractures;
prophylaxis index old/new, defined as the number of aug-
mented levels divided by the number of previous but
untreated and new fractures; augmentation type 1–3 and
level of fracture 1–3 defined as thoracic (Th3–Th11),
thoracolumbar (Th12–L2) and lumbar (L3–L5).
In the univariate analysis, the level of fracture was
revealed as a significant predictor for reoperation as well as
new fracture/refracture (radiographic) at 6 months after
surgery. A lumbar index fracture had a three times higher
risk for new fracture/refracture compared with a thoracic
(OR = 0.3, 95% CI 0.09–0.95) or thoracolumbar
(OR = 0.3, 95% CI 0.12–0.74) index fracture. The risk for
reoperation was three times higher compared with a tho-
racic (OR = 0.35, 95% CI 0.11–1.148, n.s.) and five times
higher compared with a thoracolumbar (OR = 0.21, 95%
CI 0.07–0.62) index fracture. The model gave indications
for augmentation type 3 (cranio-caudal multilevel pro-
phylaxis) to have a protective effect. Type 1 patients had a
more than twice as high new fracture/refracture (radio-
graphic) risk compared with type 3 patients (OR = 2.61,
95% CI 0.92–7.38, p = 0.12). For a reoperation, the same
tendencies were revealed. Group 1 had an about three times
higher risk compared with group 3 (OR = 2.9, 95% CI
0.94–8.949, p = 0.1). Both effects were not significant, but
both models lacked power. A total of 485 patients would be
necessary for conclusively answering if the non-significant
findings would truly remain that way or if we are currently
dealing with a beta-error.
The final multivariate model revealed male patients to
have an about three times higher new fracture/refracture
risk (radiographic) (OR = 2.78, p = 0.02) at 6 months
after surgery. Similar to the univariate analysis, patients
with a lumbar index fracture had an about three to five times
higher new fracture/refracture or reoperation risk than
patients with a thoracic (OR = 0.33/0.35, p = 0.009/0.01)
or thoracolumbar (OR = 0.32/0.22, p = 0.099/0.01) index
fracture.
Discussion
Our series reports the short-term results of the treatment of
VB compression fractures with percutaneous VP in oste-
oporotic patients. We found a significant and clinically
relevant reduction in back pain, decreased painkiller con-
sumption, increased QoL and vertebral height restoration.
The localization of the index fracture and the patient’s sex
had an influence on the 6-month radiographic new fracture/
refracture or reoperation risk. We focused on this seem-
ingly short follow-up interval, since it is known from BKP
studies that the majority of new fractures do already occur
in the first 60 days after surgery [8]. We found tendencies
for the extent of prophylactic augmentation also to have an
influence, but because of an underpowered analysis we
cannot conclusively answer this question. The underlying
disease was osteoporosis, a condition with a reduced bone
density and limited skeletal stability.
The current study showed moderate cement extrusion
rates, but much lower symptomatic extrusions compared
with the literature. Intraoperative hypotension was
observed as patients were monitored very closely and the
intervention was done under general anesthesia. No clini-
cally symptomatic cement leakages were observed in this
series [9–14]. The main reason for this may be our use of
high viscosity cement (DePuy Spine, Inc.,), which we
inject after around 12 min of polymerization time at 19
room temperature. By then, it is already too viscous to be
applied by hand with standard syringes. An additional
augmentation of adjacent and nonadjacent VBs was used to
prevent further fractures and all the related consequences,
to minimize the total number of surgeries in this multi-
morbid patient population and to consequently increase the
cost-effectiveness of the index intervention [15–17]. The
decision to perform a multilevel preventive augmentation
was based on the extent of the presence of risk factors that
the WHO FRAX tool regards as the most important
predictors for an osteoporotic fracture (http://www.shef.ac.
uk/FRAX/). These are the patient’s age, gender, comor-
bidity risk profile (e.g., renal disease, steroid treatment,
rheumatoid arthritis, secondary osteoporosis), BMI, BMD,
smoking and alcohol consumption, previous osteoporotic
VB fractures, previous osteoporotic fractures in other
bones, family history of hip fractures, and the number and
location of newly fractured VBs. The current 6-month
followup analysis of new fractures, refractures or reoper-
ations revealed that cranio-caudal multilevel prophylaxis
could be superiorly protective compared with a solely
cranial or caudal prophylaxis. The comparisons were,
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however, compromised by a lack of power. In the litera-
ture, the rate for distant or adjacent fractures is between
17 and 27% depending on the follow-up time [16–18].
Unfortunately, there is no objective parameter yet, which is
helpful for assessing the individual fracture risk of the most
vulnerable levels.
A significant improvement in the anterior and/or central
VB height could be shown. This was also reflected in a
significant pre- to postoperative improvement in the Beck
Index and local sagittal angle. Percutaneous VP and BKP,
both, have the ability to restore vertebral height and to
improve alignment [19]. For VP, however, the preoperative
dynamic mobility of the fracture is the important predictor
for the postoperative height improvement, which is mainly
achieved by a correct prone positioning maneuver and not
by the procedure itself [20].
A significant back pain reduction from 56.7, preopera-
tively, to 41.4 at the 8-week follow-up was found. The pain
reduction might appear limited, but it is still significant and
clinically relevant. However, it also reflects the fact that we
are inclined to a rather aggressive approach for the treat-
ment of osteoporotic VB compression fractures to prevent
further collapses. Therefore, we consider the intervention
as indicated even in cases with an initially moderate pain
level. The pain alleviation, reduced need for medication
and improved segmental alignment increased the QoL after
VP to a great extent.
The significant and clinically relevant pain relief we
found is also reported in other observational and random-
ized controlled study designs [21–23]. In meta-analyses
and systematic reviews of the literature, a significantly
greater improvement in pain scores was found in patients
receiving VP [24]. There was, however, no difference in
the clinical significance of pain relief between the two
treatments. In comparison to the conservative treatment
regimens, both VP and BKP are promising innovations
with the benefit of rapidly improved mobility, function and
stature, significantly decreased pain-related doctor visits
and reduced use of analgetics [25, 26]. This ultimately
leads to a prolonged survival of patients who were surgi-
cally treated [27]. The increased refracture risk of male
patients seems counterintuitive at first. Female patients
with their mostly weaker osteoporotic bone stock should
have more refractures. The fact that there are no significant
differences in reoperation risk. However, these findings
may be similarly explained as in total hip arthroplasty.
Male patients tend to have higher postoperative activity
levels that result in higher component loosening risks
[28, 29]. These activity levels may lead to a larger extent of
vertebral body sintering which we regarded as a Genant
class change of at least one unit, but not necessarily to a
manifest symptomatic event that requires reoperation.
Conclusion
VP results in immediate back pain reduction as well as
improvement of local vertebral body alignment, compared
to baseline, along with improved QoL and low rates of
complications and revisions. The type of preventive aug-
mentation may positively influence the short-term new
fracture rate in this osteoporotic patient sample without
significantly increasing the complication and extrusion
rates. Male patients and patients with a lumbar index
fracture are at an increased risk for refractures and/or
reoperations at 6 months after surgery.
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